Imran Khan, Md, PhD, Vice President of U.S. medical affairs for hematology, oncologist, Johnson & Johnson, touched on Tecvayli plus Darzalex Faspro reducing the risk of disease progression or death by 83%, and what that signals for patients.
Imran Khan, M.D., Ph.D.
Advertisement
Imran Khan, M.D., Ph.D. is Vice President, Medical Affairs for Hematology at Johnson & Johnson where he leads the team responsible for all medical aspects of the company’s Hematology portfolio in the U.S. He is known as a collaborative, forward-thinking leader who has a strong track record of innovation, talent development and stakeholder engagement.
In addition to his role at Johnson & Johnson, Imran is a Clinical Assistant Professor at the Rutgers Cancer institute of NJ, an NCI designated institution, Clinical Assistant Professor in Robert Wood Johnson Medical School, Assistant Professor at Hackensack University Medical Center and a Board Member in the CEO Roundtable on Cancer (CEORT). He is also an Adjunct Professor in the Rutgers College of Pharmacy. As a physician and pharmaceutical leader, Imran has devoted his career to understanding and treating the many forms of blood cancer.
Articles by Imran Khan, M.D., Ph.D.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Aradhana Sarin: The CFO as a Catalyst
2
Regeneron Enters $2.1 Billion Radiopharma Collaboration with Telix Pharmaceuticals
3
FDA Issues CRL to Replimune for RP1 Biologics License Application for Advanced Melanoma Treatment
4
Pharmaceutical Executive Daily: FDA Issues Second CRL for Replimune's RP1 Melanoma Treatment
5